 Jennifer Soep
Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteomyelitis | 4 | 2025 | 146 | 0.740 |
Why?
| | Education, Medical, Undergraduate | 6 | 2026 | 208 | 0.530 |
Why?
| | Lupus Erythematosus, Systemic | 6 | 2013 | 242 | 0.520 |
Why?
| | Coronary Artery Disease | 1 | 2018 | 754 | 0.350 |
Why?
| | Competency-Based Education | 2 | 2026 | 82 | 0.350 |
Why?
| | Clinical Competence | 4 | 2026 | 1260 | 0.310 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2025 | 347 | 0.280 |
Why?
| | Internship and Residency | 4 | 2026 | 1279 | 0.270 |
Why?
| | Vasculitis | 2 | 2021 | 69 | 0.260 |
Why?
| | Pediatrics | 3 | 2026 | 1139 | 0.260 |
Why?
| | Schools, Medical | 2 | 2026 | 159 | 0.240 |
Why?
| | School Admission Criteria | 1 | 2026 | 35 | 0.230 |
Why?
| | Education, Medical, Graduate | 3 | 2026 | 568 | 0.220 |
Why?
| | Drug Hypersensitivity Syndrome | 1 | 2024 | 1 | 0.210 |
Why?
| | Personnel Selection | 1 | 2026 | 92 | 0.210 |
Why?
| | Arteriosclerosis | 1 | 2004 | 83 | 0.210 |
Why?
| | Atherosclerosis | 3 | 2013 | 411 | 0.190 |
Why?
| | Heptanoic Acids | 2 | 2013 | 67 | 0.180 |
Why?
| | Antirheumatic Agents | 2 | 2018 | 308 | 0.170 |
Why?
| | Adenosine Deaminase | 1 | 2021 | 45 | 0.170 |
Why?
| | Pyrroles | 2 | 2013 | 221 | 0.170 |
Why?
| | Child | 17 | 2025 | 22980 | 0.160 |
Why?
| | Interleukin-1 | 1 | 2024 | 961 | 0.160 |
Why?
| | C-Reactive Protein | 4 | 2025 | 430 | 0.160 |
Why?
| | Models, Psychological | 1 | 2020 | 295 | 0.140 |
Why?
| | Delphi Technique | 3 | 2025 | 347 | 0.130 |
Why?
| | Infliximab | 1 | 2018 | 111 | 0.130 |
Why?
| | Adolescent | 16 | 2025 | 22826 | 0.130 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2018 | 135 | 0.130 |
Why?
| | Endothelium, Vascular | 1 | 2004 | 959 | 0.130 |
Why?
| | Blood Sedimentation | 3 | 2025 | 37 | 0.130 |
Why?
| | Learning | 2 | 2018 | 447 | 0.120 |
Why?
| | Narration | 1 | 2017 | 82 | 0.120 |
Why?
| | Coronary Vessels | 1 | 2018 | 246 | 0.120 |
Why?
| | Diagnosis, Differential | 2 | 2018 | 1518 | 0.120 |
Why?
| | Child, Preschool | 8 | 2025 | 12017 | 0.110 |
Why?
| | Echocardiography | 1 | 2018 | 652 | 0.110 |
Why?
| | Aspirin | 1 | 2018 | 406 | 0.110 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 92 | 0.110 |
Why?
| | Chronic Disease | 3 | 2025 | 1845 | 0.100 |
Why?
| | Male | 19 | 2025 | 73954 | 0.100 |
Why?
| | Humans | 27 | 2026 | 147306 | 0.100 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2014 | 99 | 0.100 |
Why?
| | Skin | 1 | 2018 | 759 | 0.100 |
Why?
| | Rheumatology | 2 | 2025 | 136 | 0.100 |
Why?
| | Students, Medical | 2 | 2017 | 380 | 0.100 |
Why?
| | Twins, Monozygotic | 1 | 2013 | 133 | 0.090 |
Why?
| | Cerebral Arterial Diseases | 1 | 2012 | 50 | 0.090 |
Why?
| | Capillaries | 1 | 2013 | 125 | 0.090 |
Why?
| | Biomarkers | 4 | 2013 | 4354 | 0.090 |
Why?
| | Polyendocrinopathies, Autoimmune | 1 | 2011 | 18 | 0.090 |
Why?
| | Lupus Nephritis | 1 | 2012 | 67 | 0.090 |
Why?
| | Remission Induction | 1 | 2012 | 310 | 0.080 |
Why?
| | Curriculum | 3 | 2026 | 1083 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2013 | 389 | 0.080 |
Why?
| | Potassium Channels | 1 | 2011 | 148 | 0.080 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 198 | 0.080 |
Why?
| | Female | 18 | 2025 | 80081 | 0.080 |
Why?
| | Connective Tissue Diseases | 1 | 2011 | 85 | 0.080 |
Why?
| | Anticholesteremic Agents | 1 | 2012 | 157 | 0.080 |
Why?
| | Fibrinolytic Agents | 1 | 2012 | 303 | 0.080 |
Why?
| | Lung Diseases | 2 | 2013 | 787 | 0.070 |
Why?
| | Thrombophilia | 1 | 2009 | 89 | 0.070 |
Why?
| | Carotid Artery, Common | 1 | 2009 | 32 | 0.070 |
Why?
| | Tunica Intima | 1 | 2009 | 79 | 0.070 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2013 | 448 | 0.070 |
Why?
| | Arthritis, Juvenile | 1 | 2009 | 64 | 0.070 |
Why?
| | Lipoproteins, LDL | 2 | 2010 | 119 | 0.070 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 253 | 0.070 |
Why?
| | Hemorrhage | 1 | 2013 | 832 | 0.070 |
Why?
| | Cholesterol, LDL | 2 | 2013 | 363 | 0.070 |
Why?
| | Venous Thromboembolism | 1 | 2012 | 330 | 0.070 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 840 | 0.060 |
Why?
| | Age of Onset | 2 | 2009 | 568 | 0.060 |
Why?
| | Prospective Studies | 5 | 2026 | 8166 | 0.060 |
Why?
| | Brain Ischemia | 1 | 2009 | 362 | 0.060 |
Why?
| | Chilblains | 1 | 2005 | 3 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2014 | 1220 | 0.060 |
Why?
| | Apolipoprotein A-I | 1 | 2004 | 39 | 0.050 |
Why?
| | Antigen-Antibody Complex | 1 | 2004 | 70 | 0.050 |
Why?
| | Spinal Diseases | 1 | 2024 | 50 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1287 | 0.050 |
Why?
| | Cholesterol, HDL | 1 | 2004 | 202 | 0.050 |
Why?
| | Treatment Outcome | 5 | 2025 | 11947 | 0.050 |
Why?
| | Risk Factors | 5 | 2012 | 11017 | 0.050 |
Why?
| | Faculty, Medical | 2 | 2017 | 308 | 0.050 |
Why?
| | Double-Blind Method | 3 | 2013 | 2080 | 0.050 |
Why?
| | Spine | 1 | 2024 | 184 | 0.050 |
Why?
| | Carotid Intima-Media Thickness | 2 | 2013 | 75 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3980 | 0.040 |
Why?
| | Severe Combined Immunodeficiency | 1 | 2021 | 22 | 0.040 |
Why?
| | Infant | 4 | 2024 | 10195 | 0.040 |
Why?
| | United States | 3 | 2026 | 16313 | 0.040 |
Why?
| | Agammaglobulinemia | 1 | 2021 | 36 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2025 | 17561 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 2017 | 0.040 |
Why?
| | Consensus | 1 | 2022 | 476 | 0.040 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2021 | 376 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2004 | 901 | 0.040 |
Why?
| | Cytokines | 2 | 2021 | 2087 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2011 | 1977 | 0.040 |
Why?
| | Cardiovascular Diseases | 1 | 2010 | 2218 | 0.030 |
Why?
| | Inflammation | 1 | 2009 | 2921 | 0.030 |
Why?
| | Prevalence | 1 | 2024 | 2889 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2004 | 3660 | 0.030 |
Why?
| | Colorado | 3 | 2012 | 4591 | 0.030 |
Why?
| | Endothelial Cells | 1 | 2021 | 886 | 0.030 |
Why?
| | Time Factors | 2 | 2020 | 7173 | 0.030 |
Why?
| | Disease Progression | 2 | 2013 | 2892 | 0.030 |
Why?
| | Young Adult | 4 | 2012 | 14437 | 0.020 |
Why?
| | Prognosis | 2 | 2012 | 4384 | 0.020 |
Why?
| | Polysaccharides | 1 | 2012 | 89 | 0.020 |
Why?
| | Antiphospholipid Syndrome | 1 | 2012 | 37 | 0.020 |
Why?
| | Puberty | 1 | 2013 | 137 | 0.020 |
Why?
| | Carotid Arteries | 1 | 2013 | 208 | 0.020 |
Why?
| | Enoxaparin | 1 | 2012 | 68 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2012 | 306 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 95 | 0.020 |
Why?
| | Immunomodulation | 1 | 2012 | 100 | 0.020 |
Why?
| | Focus Groups | 1 | 2014 | 587 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2011 | 68 | 0.020 |
Why?
| | Follow-Up Studies | 2 | 2011 | 5478 | 0.020 |
Why?
| | Syndrome | 1 | 2011 | 385 | 0.020 |
Why?
| | Rituximab | 1 | 2011 | 211 | 0.020 |
Why?
| | Familial Primary Pulmonary Hypertension | 1 | 2011 | 196 | 0.020 |
Why?
| | Mutation | 1 | 2021 | 4130 | 0.020 |
Why?
| | Placebos | 1 | 2010 | 193 | 0.020 |
Why?
| | Echocardiography, Doppler | 1 | 2011 | 118 | 0.020 |
Why?
| | Lipoproteins, HDL | 1 | 2010 | 104 | 0.020 |
Why?
| | Lipoprotein(a) | 1 | 2010 | 70 | 0.020 |
Why?
| | Montana | 1 | 2009 | 18 | 0.020 |
Why?
| | Recurrence | 1 | 2012 | 1151 | 0.020 |
Why?
| | Utah | 1 | 2009 | 83 | 0.020 |
Why?
| | Factor VIII | 1 | 2009 | 107 | 0.020 |
Why?
| | Azathioprine | 1 | 2009 | 44 | 0.020 |
Why?
| | Immunologic Factors | 1 | 2011 | 261 | 0.020 |
Why?
| | Drug Tolerance | 1 | 2009 | 99 | 0.020 |
Why?
| | Cholesterol | 1 | 2010 | 410 | 0.020 |
Why?
| | Receptors, Interleukin-1 | 1 | 2009 | 211 | 0.020 |
Why?
| | Triglycerides | 1 | 2010 | 529 | 0.020 |
Why?
| | Prednisone | 1 | 2009 | 230 | 0.020 |
Why?
| | Lipoproteins | 1 | 2009 | 166 | 0.020 |
Why?
| | Creatinine | 1 | 2009 | 516 | 0.020 |
Why?
| | Anticoagulants | 1 | 2012 | 751 | 0.020 |
Why?
| | Lipids | 1 | 2012 | 723 | 0.010 |
Why?
| | Qualitative Research | 1 | 2014 | 1735 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2009 | 487 | 0.010 |
Why?
| | Age Factors | 1 | 2013 | 3372 | 0.010 |
Why?
| | Ultrasonography | 1 | 2009 | 795 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2030 | 0.010 |
Why?
| | Adult | 2 | 2005 | 41406 | 0.010 |
Why?
| | Autoantibodies | 1 | 2011 | 1513 | 0.010 |
Why?
| | Sex Factors | 1 | 2009 | 2136 | 0.010 |
Why?
| | Incidence | 1 | 2009 | 2954 | 0.010 |
Why?
| | Acute Disease | 1 | 2005 | 1049 | 0.010 |
Why?
| | Cohort Studies | 1 | 2012 | 6099 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2791 | 0.010 |
Why?
| | Body Mass Index | 1 | 2009 | 2470 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2010 | 6011 | 0.010 |
Why?
|
|
Soep's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|